Proposed
Bill · 119th Congress · HR 8032
FAIC Act
Refreshed 2 h ago
Introduced 2026-03-20Topic: health careSummary
AI-generated summary, report an errorThis bill changes how Medicare pays hospital outpatient departments for certain cancer drugs and biologicals. Starting in 2026, Medicare would pay separately for these products, instead of bundling their payment into the payment for a related outpatient service, if their estimated average cost per day is at least $350. The $350 threshold would rise each year by the outpatient fee schedule increase factor. The separate payment would generally be based on the product's average sales price, or on other cost measures if that data is not available. The bill applies to cancer drugs approved by the FDA on or after January 1, 2008, and requires Medicare to adjust other payments so total spending stays the same.
Sponsors
- Neal P. Dunn Republican sponsor
- 6 cosponsors
Action history
| Date | Chamber | Action | Status effect |
|---|---|---|---|
| 2026-03-20 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | refer |
| 2026-03-20 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | refer |
| 2026-03-20 | Introduced in House | introduce | |
| 2026-03-20 | Introduced in House | introduce |